Celldex Therapeutics, Inc.
1 day chart
Celldex Therapeutics, Inc. is a biopharmaceutical company. It is focused on developing therapeutic monoclonal and bispecific antibodies that address diseases for which available treatments are inadequate. Its drug candidates include antibody-based therapeutics, which has the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. Its bispecific platform includes CDX-585 and CDX-527. CDX-585 combines its active PD-1 blockade and anti-ILT4 blockade to prevent immunosuppressive signals in T cells and myeloid cells, respectively. Its other programs include CDX-1140, a fully human agonist monoclonal antibody targeted to CD40.
Buy US stocks in Australia starting with CLDX. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in CLDX
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.